Ophthalmology Times

We at Ophthalmology Times want you to get the most out of our content and news coverage, so we're asking you what you want to see most! Help us to ensure that we are providing the highest and most relevant content to you. Cast your vote in the poll below. If you have additional ideas or favorite pieces already on our website that you'd like to see more of share them in the comments! We appreciate your participation.

A newly published study reported that higher mean blood pressure (BP) levels and higher standard deviation (SD) of BP are associated with faster progression of visual field (VF) defects in patients with glaucoma. They pointed out that the association between blood pressure (BP) and glaucoma progression has been studied previously. Impaired autoregulation of the vasculature, especially in the optic nerve head, was proposed as a key risk factor for glaucomatous progression. However, it remains uncertain whether these vascular changes are a cause or a consequence of glaucoma, they commented. Read More: https://ow.ly/51th50U9uX6

The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class investigational candidate, topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease. At the same time, Aldeyra is choosing to expand their option agreement with AbbVie, granting the manufacturer more cash to bring the drug to market. Read More: https://ow.ly/FU2O50UaUgL

Emmecell announced promising topline results from its U.S. multicenter Phase 1 extension study evaluating EO2002, a nonsurgical cell therapy for corneal edema. The company noted that its randomized, double-masked trial demonstrated improvements in vision and corneal health, along with a strong safety profile. Read More: https://ow.ly/J1Gh50U9uRW

A binocular, eye tracking–based amblyopia home treatment (CureSight; NovaSight) has been shown to be at least as effective as patching, according to the study's lead author Tamara Wygnanski-Jaffe, MD, of the Goldschleger Eye Institute; head of the Pediatric Ophthalmology and Strabismus Clinic, Sheba Medical Center, Tel HaShomer, Israel; and the Faculty of Medicine, Ophthalmology, Tel Aviv University, Israel. The study, published in the American Journal of Ophthalmology, found that patients who adhered to the treatment protocol using the amblyopia home treatment program obtained greater visual acuity (VA) increases compared with those who used patching to treat amblyopia. Read More: https://ow.ly/m2cg50U9XUs

Innovation in ophthalmology often arises from unexpected sources, driven by collaboration between researchers and clinicians. Here, 2 pioneering clinician-scientists specializing in the cornea share their insights on the origins of their innovations, the journey to realization, and the essence of being a clinician-scientist. Read More: https://ow.ly/e33b50U93uC

LumiThera Inc. announced the US Food & Drug Administration (FDA) has authorized marketing of Valeda Light Delivery System for the treatment of patients with dry age-related macular degeneration (AMD). According to the company, the Valeda Light Delivery System is the first-ever authorized treatment by the FDA for vision loss in dry AMD patients and provides an improvement in best corrected visual acuity (BCVA) over 24 months of >5 letters or equivalent Read More: https://ow.ly/wfU550U1GHM

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by Samsung Bioepis. The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. It has been approved for use in adult patients for the treatment of neovascular (wet) age related macular degeneration (AMD), visual impairment due to macular edema secondary to retinal vein occlusion (RVO; branch or central RVO), visual impairment due to diabetic macular edema (DME), and visual impairment due to myopic choroidal neovascularization (myopic CNV). Read More: https://ow.ly/vlFk50U9uLt

The FDA approved teprotumumab-trbw (Tepezza; Amgen) in 2020 for treating thyroid eye disease (TED) following promising results from clinical trials. Although thousands of patients have received the monoclonal antibody, which targets the insulin-like growth factor 1 receptor, its use in clinical practice remains relatively new, and long-term real-world data remain limited. The results of 2 recent real-world studies show encouraging outcomes and indicate that the drug is performing well for a high percentage of patients with TED regarding the need for retreatments and intervention with orbital decompression. Read More: https://ow.ly/WcrM50U90sl

Astellas Pharma Inc. announced the FDA has issued a Complete Response Letter (CRL) for its supplemental New Drug Application for avacincaptad pegol intravitreal solution (IZERVAY). The FDA stated it cannot approve a supplemental New Drug Application in its present form. IZERVAY had an expected Prescription Drug User Fee Act (PDUFA) date of November 19. Read More: https://ow.ly/Gaw150U9XRV